ARCUTIS BIOTHERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Increase (Decrease) in Accrued Liabilities of $30.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $9.96M, a 53.11% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $20.77M.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $23.45M, a 77.90% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $5.57M, a 44.94% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $50.04M, a 56.23% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $32.03M, a 472.63% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $5.59M, a 368.90% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $1.19M, a 88.60% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $30.72M 10-Q · filed 2026-08-05 | $54.17M derived: sum of 3 quarters · filed 2026-08-05 | $59.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $20.77M 10-Q · filed 2026-05-06 | $44.22M derived: sum of 2 quarters · filed 2026-05-06 | $49.79M derived: sum of 3 quarters · filed 2026-05-06 | $71.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $23.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $29.03M derived: sum of 2 quarters · filed 2026-02-25 | $50.26M derived: sum of 3 quarters · filed 2026-08-05 | $50.04M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $26.81M derived: sum of 2 quarters · filed 2026-08-05 | $26.59M 10-Q · filed 2025-10-28 | $39.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $21.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $21.02M 10-Q · filed 2026-08-05 | $34.20M derived: sum of 3 quarters · filed 2026-08-05 | $44.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$214.00K 10-Q · filed 2026-05-06 | $12.97M derived: sum of 2 quarters · filed 2026-05-06 | $23.09M derived: sum of 3 quarters · filed 2026-05-06 | $32.15M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $13.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $23.31M derived: sum of 2 quarters · filed 2026-02-25 | $32.37M derived: sum of 3 quarters · filed 2026-02-25 | $32.03M 10-K · filed 2026-02-25 |
| 2024-09-30 | $10.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $19.18M derived: sum of 2 quarters · filed 2025-10-28 | $18.85M 10-Q · filed 2025-10-28 | $24.77M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $9.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $8.73M 10-Q · filed 2025-08-06 | $14.64M derived: sum of 3 quarters · filed 2026-02-25 | $23.84M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$332.00K 10-Q · filed 2025-05-06 | $5.58M derived: sum of 2 quarters · filed 2026-02-25 | $14.79M derived: sum of 3 quarters · filed 2026-02-25 | $9.72M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.12M derived: sum of 2 quarters · filed 2026-02-25 | $10.05M derived: sum of 3 quarters · filed 2026-02-25 | $5.59M 10-K · filed 2026-02-25 |
| 2023-09-30 | $9.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.14M derived: sum of 2 quarters · filed 2024-11-06 | -$323.00K 10-Q · filed 2024-11-06 | $293.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$5.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$9.52M 10-Q · filed 2024-08-14 | -$8.91M derived: sum of 3 quarters · filed 2025-02-25 | -$1.29M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$4.46M 10-Q · filed 2024-05-14 | -$3.84M derived: sum of 2 quarters · filed 2025-02-25 | $3.78M derived: sum of 3 quarters · filed 2025-02-25 | $2.27M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $8.24M derived: sum of 2 quarters · filed 2025-02-25 | $6.72M derived: sum of 3 quarters · filed 2025-02-25 | $1.19M 10-K · filed 2025-02-25 |
| 2022-09-30 | $7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $6.11M derived: sum of 2 quarters · filed 2023-11-03 | $577.00K 10-Q · filed 2023-11-03 | $12.26M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$7.04M 10-Q · filed 2023-08-08 | $4.64M derived: sum of 3 quarters · filed 2024-02-27 | $8.00M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$5.53M 10-Q · filed 2023-05-09 | $6.15M derived: sum of 2 quarters · filed 2024-02-27 | $9.51M derived: sum of 3 quarters · filed 2024-02-27 | $7.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $11.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $15.05M derived: sum of 2 quarters · filed 2024-02-27 | $13.46M derived: sum of 3 quarters · filed 2024-02-27 | $10.46M 10-K · filed 2024-02-27 |
| 2021-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.78M derived: sum of 2 quarters · filed 2022-11-08 | -$1.22M 10-Q · filed 2022-11-08 | -$1.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$4.58M 10-Q · filed 2022-08-04 | -$5.31M derived: sum of 3 quarters · filed 2023-02-28 | -$303.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$3.00M 10-Q · filed 2022-05-05 | -$3.73M derived: sum of 2 quarters · filed 2023-02-28 | $1.28M derived: sum of 3 quarters · filed 2023-02-28 | $5.01M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$725.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.28M derived: sum of 2 quarters · filed 2023-02-28 | $8.01M derived: sum of 3 quarters · filed 2023-02-28 | $11.88M 10-K · filed 2023-02-28 |
| 2020-09-30 | $5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.73M derived: sum of 2 quarters · filed 2021-11-04 | $12.60M 10-Q · filed 2021-11-04 | $11.14M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $7.59M 10-Q · filed 2021-08-05 | $6.13M derived: sum of 3 quarters · filed 2022-02-22 | $8.95M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $3.87M 10-Q · filed 2021-05-06 | $2.40M derived: sum of 2 quarters · filed 2022-02-22 | $5.23M derived: sum of 3 quarters · filed 2022-02-22 | $5.89M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $1.36M derived: sum of 2 quarters · filed 2022-02-22 | $2.02M derived: sum of 3 quarters · filed 2022-02-22 | $2.39M 10-K · filed 2022-02-22 |
| 2019-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.48M derived: sum of 2 quarters · filed 2020-11-05 | $3.85M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $659.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $1.03M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $370.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $601.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |